Inovio’s Voceryq already received accelerated approval granted by the FDA to treat adults with recurrent respiratory papillomatosis.
RT’s Three Key Takeaways:
- Regulatory Submission: Inovio has submitted a conditional marketing authorization application to the European Medicines Agency for Voceryq to treat adults with recurrent respiratory papillomatosis.
- Surgical Burden Reduction: The DNA-based immunotherapy targets HPV-6 and HPV-11 antigens to reduce the frequency of repeated surgical procedures that put patients’ vocal cords and airway function at risk.
- Recent Regulatory History: The European filing follows accelerated approval granted by the Food and Drug Administration (FDA) on Oct 30, 2026, with an expected US commercial launch in early 2027.
Inovio has submitted a conditional marketing authorization application to the European Medicines Agency (EMA) for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously referred to as INO-3107, as a treatment for adults with recurrent respiratory papillomatosis (RRP), according to the company.
The submission follows accelerated approval granted by the FDA on Oct 30, 2026, to reduce the frequency of surgical papilloma excisions in adult patients. According to Inovio, Voceryq is the first FDA-approved plasmid DNA-based immunotherapy.
“Building on the recent FDA approval of Voceryq, we believe there’s significant opportunity to transform the treatment paradigm for RRP in Europe, a region that currently has no approved non-surgical treatment options that target the root cause of RRP,” said Michael Sumner, chief medical officer of Inovio, in a news release. “We look forward to working closely with the EMA during the review and hope to ultimately provide RRP patients with a much-needed new treatment option that reduces the need for surgery.”
Impact on Airway and Vocal Cord Management
RRP is a rare, debilitating condition primarily caused by human papillomavirus types HPV-6 and HPV-11. The disease causes wart-like papillomas to develop throughout the respiratory tract, leading to hoarseness, speech limitations, and potentially life-threatening airway obstruction.
Repeated surgical debulking serves as the current standard of care; however, lesions frequently recur. Based on company claims data analysis, an estimated prevalent population of at least 25,000 patients live with RRP in the US, with additional cases diagnosed annually.
“Clinicians and patients alike understand that every surgery matters, because every surgery puts a patient’s vocal cords at risk,” said Frederik Dikkers, professor emeritus of otorhinolaryngology / head and neck surgery at Amsterdam University Medical Center, in a news release. “RRP affects patients around the world, and this submission is a meaningful step forward for those in Europe who have waited far too long for relief from this debilitating disease.”
Clinical Evidence and Regulatory Path
According to Inovio, the European marketing application includes preclinical, clinical, and manufacturing data, incorporating trial results published in Nature Communications and The Laryngoscope in 2025, alongside an additional data analysis published in The Laryngoscope in October 2026.
Voceryq received orphan drug designation from the European Commission in 2023, as well as Advanced Therapy Medicinal Product certification from the EMA Committee for Advanced Therapies. The therapy is administered via the Cellectra 5PSP electroporation delivery device, which holds a CE mark in the European Union.
Under the standard treatment regimen, patients receive an initial surgical excision of visible papilloma followed by a 9-week dosing course without mandatory subsequent surgical interventions. According to prescribing information cited in the release, common adverse reactions exceeding a 5% incidence rate include injection site reactions, headache, fatigue, hypertension, nausea, and dizziness.
In the US, Inovio expects product ordering and shipment to begin within roughly 60 days of its late October approval, leading up to a full commercial launch in the first quarter of 2027. Continued approval under the accelerated pathway remains contingent on confirming clinical efficacy in upcoming confirmatory trials, according to the announcement.